BAJAJ BROKING

Notification
No new Notification messages
Nisus Finance Services IPO is Open!
Apply for the Nisus Finance Services IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Q2 FY'24-25 Results of Top Companies
Reliance, TCS, HDFC Bank & more: Explore key financial highlights from India's top quarterly results.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
NSE BSE
gennex laboratories ltd. stock

GENNEX LABORATORIES LTD. Share Price

18.87 -0.21 (-1.10%)
Dec 04 2024 03:30 PM Pharmaceuticals NSE: GENNEX

GENNEX LABORATORIES LTD. Share Price Update

As of the latest trading session, GENNEX LABORATORIES LTD. share price is currently at 18.87, which is down by -0.21 from its previous closing. Today, the stock has fluctuated between 18.80 and 19.20. Over the past year, GENNEX LABORATORIES LTD. has achieved a return of 16.26 %. In the last month alone, the return has been -6.46 %. Read More...

GENNEX LABORATORIES LTD. Performance

Day Range

Low18.80 High19.20
18.87

52 Week Range

Low 13.25 High 29.00
18.87

GENNEX LABORATORIES LTD. Share Price

531739

GENNEX

img img img img
No Data Available

Open Price

19.09

Prev. Close

19.09

Volume (Shares)

432354.00

Total traded value

81.99

Upper Circuit

20.04

Lower Circuit

18.14

Note: The current prices & values are delayed, Login to your account for live updates.

GENNEX LABORATORIES LTD. Fundamentals


(Standalone)

Market Cap (Cr) 429.19
PE Ratio (TTM) 29.37
Book Value / Share 7.62
Beta 0.59
ROE 9.45%
EPS (TTM) 0.65
Dividend Yield 0.00%
Net Profit Qtr (Cr) 4.16

GENNEX LABORATORIES LTD. Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars SEP 2024 (Values in Cr)
Revenue 24.69
Operating Expense 21.50
Net Profit 4.16
Net Profit Margin (%) 16.84
Earnings Per Share (EPS) 0.18
EBITDA 5.52
Effective Tax Rate (%) 16.96
Particulars JUN 2024 (Values in Cr)
Revenue 21.33
Operating Expense 18.86
Net Profit 4.17
Net Profit Margin (%) 19.54
Earnings Per Share (EPS) 0.18
EBITDA 5.38
Effective Tax Rate (%) 15.24
Particulars MAR 2024 (Values in Cr)
Revenue 21.33
Operating Expense 18.69
Net Profit 3.93
Net Profit Margin (%) 18.42
Earnings Per Share (EPS) 0.24
EBITDA 5.06
Effective Tax Rate (%) 14.75
Particulars DEC 2023 (Values in Cr)
Revenue 17.08
Operating Expense 16.16
Net Profit 2.64
Net Profit Margin (%) 15.45
Earnings Per Share (EPS) 0.15
EBITDA 3.68
Effective Tax Rate (%) 16.45
Particulars SEP 2023 (Values in Cr)
Revenue 14.24
Operating Expense 10.76
Net Profit 2.66
Net Profit Margin (%) 18.67
Earnings Per Share (EPS) 0.15
EBITDA 4.03
Effective Tax Rate (%) 25.07
Particulars MAR 2024 (Values in Cr)
Revenue 66.80
Operating Expense 56.34
Net Profit 11.80
Net Profit Margin (%) 17.66
Earnings Per Share (EPS) 0.70
EBITDA 16.72
Effective Tax Rate (%) 20.06
Particulars MAR 2023 (Values in Cr)
Revenue 65.10
Operating Expense 62.48
Net Profit 4.56
Net Profit Margin (%) 7.00
Earnings Per Share (EPS) 0.26
EBITDA 7.98
Effective Tax Rate (%) 24.12
Particulars MAR 2022 (Values in Cr)
Revenue 61.21
Operating Expense 57.50
Net Profit 3.92
Net Profit Margin (%) 6.40
Earnings Per Share (EPS) 0.33
EBITDA 6.76
Effective Tax Rate (%) 22.98
Particulars MAR 2021 (Values in Cr)
Revenue 59.65
Operating Expense 54.74
Net Profit 4.04
Net Profit Margin (%) 6.77
Earnings Per Share (EPS) 0.32
EBITDA 6.68
Effective Tax Rate (%) 20.15
Particulars MAR 2020 (Values in Cr)
Revenue 55.62
Operating Expense 54.13
Net Profit 1.86
Net Profit Margin (%) 3.34
Earnings Per Share (EPS) 0.15
EBITDA 4.31
Effective Tax Rate (%) 27.05
Particulars MAR 2024 (Values in Cr)
Book Value / Share 7.24
ROE % 10.51
ROCE % 13.64
Total Debt to Total Equity 0.03
EBITDA Margin 22.31
Particulars MAR 2023 (Values in Cr)
Book Value / Share 4.46
ROE % 7.91
ROCE % 10.17
Total Debt to Total Equity 0.09
EBITDA Margin 12.02
Particulars MAR 2022 (Values in Cr)
Book Value / Share 3.46
ROE % 9.35
ROCE % 11.78
Total Debt to Total Equity 0.21
EBITDA Margin 10.36
Particulars MAR 2021 (Values in Cr)
Book Value / Share 3.14
ROE % 10.67
ROCE % 13.16
Total Debt to Total Equity 0.16
EBITDA Margin 10.49
Particulars MAR 2020 (Values in Cr)
Book Value / Share 2.82
ROE % 5.34
ROCE % 8.33
Total Debt to Total Equity 0.14
EBITDA Margin 7.17
Particulars MAR 2024 (Values in Cr)
Book Value / Share 7.26
ROE % 9.45
ROCE % 12.50
Total Debt to Total Equity 0.01
EBITDA Margin 22.59
Particulars MAR 2023 (Values in Cr)
Book Value / Share 4.39
ROE % 7.41
ROCE % 10.69
Total Debt to Total Equity 0.09
EBITDA Margin 11.20
Particulars MAR 2022 (Values in Cr)
Book Value / Share 3.48
ROE % 9.35
ROCE % 11.78
Total Debt to Total Equity 0.21
EBITDA Margin 10.36
Particulars MAR 2021 (Values in Cr)
Book Value / Share 3.15
ROE % 10.67
ROCE % 13.16
Total Debt to Total Equity 0.16
EBITDA Margin 10.49
Particulars MAR 2020 (Values in Cr)
Book Value / Share 2.83
ROE % 5.33
ROCE % 8.31
Total Debt to Total Equity 0.14
EBITDA Margin 7.17
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 60.97
Total Assets 229.98
Total Liabilities 229.98
Total Equity 176.46
Share Outstanding 227447674
Price to Book Ratio 2.18
Return on Assets (%) 5.72
Return on Capital (%) 7.23
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 15.06
Total Assets 132.31
Total Liabilities 132.31
Total Equity 86.51
Share Outstanding 180192662
Price to Book Ratio 1.28
Return on Assets (%) 3.71
Return on Capital (%) 5.62
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 8.31
Total Assets 68.02
Total Liabilities 68.02
Total Equity 43.81
Share Outstanding 126503000
Price to Book Ratio 2.16
Return on Assets (%) 5.76
Return on Capital (%) 7.27
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.06
Total Assets 58.90
Total Liabilities 58.90
Total Equity 39.70
Share Outstanding 126503000
Price to Book Ratio 1.24
Return on Assets (%) 6.85
Return on Capital (%) 8.58
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 0.91
Total Assets 56.94
Total Liabilities 56.94
Total Equity 35.67
Share Outstanding 126503000
Price to Book Ratio 0.66
Return on Assets (%) 3.25
Return on Capital (%) 4.57
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 60.96
Total Assets 205.33
Total Liabilities 205.33
Total Equity 170.75
Share Outstanding 227447674
Price to Book Ratio 2.18
Return on Assets (%) 5.74
Return on Capital (%) 6.87
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 14.45
Total Assets 96.22
Total Liabilities 96.22
Total Equity 79.01
Share Outstanding 180192661
Price to Book Ratio 1.28
Return on Assets (%) 4.73
Return on Capital (%) 5.7
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 8.31
Total Assets 68.20
Total Liabilities 68.20
Total Equity 43.99
Share Outstanding 126503000
Price to Book Ratio 2.16
Return on Assets (%) 5.75
Return on Capital (%) 7.25
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.06
Total Assets 59.08
Total Liabilities 59.08
Total Equity 39.89
Share Outstanding 126503000
Price to Book Ratio 1.24
Return on Assets (%) 6.83
Return on Capital (%) 8.55
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 0.91
Total Assets 57.12
Total Liabilities 57.12
Total Equity 35.85
Share Outstanding 126503000
Price to Book Ratio 0.66
Return on Assets (%) 3.24
Return on Capital (%) 4.55
Particulars MAR 2024 (Values in Cr)
Net Income 16.49
Cash from Operations -46.68
Cash from Investing 18.91
Cash from Financing 73.68
Net change in Cash 45.91
Free Cash Flow -46.68
Particulars MAR 2023 (Values in Cr)
Net Income 6.37
Cash from Operations 23.67
Cash from Investing -38.32
Cash from Financing 21.03
Net change in Cash 6.38
Free Cash Flow 63.46
Particulars MAR 2022 (Values in Cr)
Net Income 5.27
Cash from Operations 13.01
Cash from Investing -2.46
Cash from Financing -1.83
Net change in Cash 7.61
Free Cash Flow 14.61
Particulars MAR 2021 (Values in Cr)
Net Income 5.06
Cash from Operations 0.09
Cash from Investing -0.02
Cash from Financing 1.61
Net change in Cash 0.15
Free Cash Flow 0.17
Particulars MAR 2020 (Values in Cr)
Net Income 2.54
Cash from Operations -1.66
Cash from Investing -0.21
Cash from Financing -0.34
Net change in Cash -2.23
Free Cash Flow -1.37
Particulars MAR 2024 (Values in Cr)
Net Income 14.86
Cash from Operations -32.33
Cash from Investing 0.92
Cash from Financing 79.01
Net change in Cash 46.51
Free Cash Flow -29.49
Particulars MAR 2023 (Values in Cr)
Net Income 6.01
Cash from Operations -14.45
Cash from Investing -0.76
Cash from Financing 21.35
Net change in Cash 6.13
Free Cash Flow -12.22
Particulars MAR 2022 (Values in Cr)
Net Income 5.27
Cash from Operations 7.74
Cash from Investing -1.26
Cash from Financing 1.86
Net change in Cash 7.24
Free Cash Flow 8.13
Particulars MAR 2021 (Values in Cr)
Net Income 5.06
Cash from Operations 0.09
Cash from Investing -0.02
Cash from Financing 1.61
Net change in Cash 0.15
Free Cash Flow 0.17
Particulars MAR 2020 (Values in Cr)
Net Income 2.54
Cash from Operations -1.66
Cash from Investing -0.21
Cash from Financing -0.34
Net change in Cash -2.23
Free Cash Flow -1.37
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 58.42 33.57 3.18 447.69 37.54 / 77.70
BLISS GVS PHARMA LTD 163.60 20.48 1.70 1722.74 92.25 / 172.40
CIPLA LTD 1534.40 26.84 4.36 123920.06 1192.85 / 1702.00
FERMENTA BIOTECH LIMITED 406.85 141.27 4.12 1197.40 145.00 / 413.80
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 58.42 50.80 9.93 447.69 37.54 / 77.70
AMRUTAJAN HEALTH LTD 749.60 45.60 7.27 2167.14 556.05 / 861.40
ASTRAZENECA PHARMA IND LT 6597.95 128.14 24.28 16494.88 4050.15 / 8139.85
BLISS GVS PHARMA LTD 163.60 21.30 1.68 1722.74 92.25 / 172.40

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 18.90
  • 26 Days 19.70
  • 10 Days 19.00
  • 50 Days 21.20
  • 12 Days 19.00
  • 100 Days 19.50
  • 20 Days 19.50
  • 200 Days 20.00
18.98
PIVOT
First Resistance 19.25
Second Resistance 19.73
Third Resistance 20.00
First Support 18.50
Second Support 18.23
Third Support 17.75
RSI 38.55
MACD -0.67
Commodity Channel Index (CCI) -69.51
ADX 33.37
Williams % R -72.70

Over 1 Month

down

-6.46

Over 3 Months

down

6.64

Over 6 Months

down

12.49

Over 1 Year

down

16.26

Over 3 Years

down

37.83

Over 5 Years

down

47.43

GENNEX LABORATORIES LTD. Future

Future: Price

25 May
0 100 200 300 400 500 600

Discount/Premium

25 May
0 1 2 3 4 5 6 7

Active Calls

25 May
0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul
0 500 1000 1500 2000 2500

GENNEX LABORATORIES LTD. Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Others
81.58
Promoter Holdings
18.41
FII
0.0
DII
0.0
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Premier Fiscal Services Private Limited Shareholding of Promoter and Promoter Group 3.7538E7 16.5
Jms Mines & Minerals Private Limited Public Shareholding 7900000.0 3.47
Vidya Tradecon Private Limited Public Shareholding 5000000.0 2.2
Brij Bhushan Agarwal Public Shareholding 4500000.0 1.98
Sumitra Devi Agarwal Public Shareholding 4500000.0 1.98
Hemant Kumar Jain Public Shareholding 4000000.0 1.76
Sanjay Kumar Public Shareholding 3726850.0 1.64
Rajababu Sampatrao Bandela Public Shareholding 3427580.0 1.51
Vab Ventures Limited Shareholding of Promoter and Promoter Group 3432170.0 1.51
Subhash Chand Bhura Trusteeof Anuj Bhura Welfare Trust Shareholding of Promoter and Promoter Group 765450.0 0.34
India Securities Brooking Private Limited Shareholding of Promoter and Promoter Group 60384.0 0.03
Prudential Investment Limited Shareholding of Promoter and Promoter Group 39820.0 0.02
Vinod Baid Shareholding of Promoter and Promoter Group 48000.0 0.02
Vab Capital Advisors Private Limited Shareholding of Promoter and Promoter Group 1500.0 0.0
Gopalakrishnan Muralidharan Tiruvarur Shareholding of Promoter and Promoter Group 150.0 0.0
Arihant Baid Shareholding of Promoter and Promoter Group 150.0 0.0

GENNEX LABORATORIES LTD.

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
Ex-Date Ex-Bonus Ratio
Ex-Date Old FV NEW FV Record Date
2009-12-14 10.0 1.0 2009-12-15

Learn More About Stocks

About GENNEX LABORATORIES LTD.

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by GENNEX LABORATORIES LTD.

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Gennex Laboratories Ltd?

Answer Field

The share price of Gennex Laboratories Ltd for NSE is ₹ 0.00 and for BSE is ₹ 18.87.

What is the Market Cap of Gennex Laboratories Ltd?

Answer Field

The market cap of Gennex Laboratories Ltd for NSE is ₹ 0.0 Cr. and for BSE is ₹ 4,29.20 Cr. as of now.

What is the 52 Week High and Low of Gennex Laboratories Ltd?

Answer Field

The 52 Week High and Low of Gennex Laboratories Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 29.00 and ₹ 13.25.

How to Buy Gennex Laboratories Ltd share?

Answer Field

You can trade in Gennex Laboratories Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Gennex Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been 16.26%.

What is the Current Share Price of Gennex Laboratories Ltd?

Answer Field

Gennex Laboratories Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 18.87 as on Dec 04 2024 03:30 PM.

What is the Market Cap of Gennex Laboratories Ltd Share?

Answer Field

The market cap of Gennex Laboratories Ltd for NSE ₹ 0.0 & for BSE ₹ 4,29.20 as on Dec 04 2024 03:30 PM.

What is the P/E Ratio of Gennex Laboratories Ltd Share?

Answer Field

As on Dec 04 2024 03:30 PM the price-to-earnings (PE) ratio for Gennex Laboratories Ltd share is 29.37.

What is the PB ratio of Gennex Laboratories Ltd Share?

Answer Field

As on Dec 04 2024 03:30 PM, the price-to-book (PB) ratio for Gennex Laboratories Ltd share is 7.62.

How to Buy Gennex Laboratories Ltd Share?

Answer Field

You can trade in Gennex Laboratories Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Gennex Laboratories Ltd Share on Bajaj Broking App?

Answer Field

To buy Gennex Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Gennex Laboratories Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs + Users

icon-with-text

4.8+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5000+ Cr MTF Book

icon-with-text
loader